Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/β-catenin signaling pathway

Clinical Cancer Research

Volumn 12, Issue 2, 2006, Pages 383-391

  Urakami, Shinji ^a,b   Shiina, Hiroaki ^b   Enokida, Hideki ^a   Kawakami, Toshifumi ^a   Tokizane, Takashi ^a   Ogishima, Tatsuya ^a   Tanaka, Yuichiro ^a   Li, Long Cheng ^a   Ribeiro Filho, Leopoldo A ^a   Terashima, Masaharu ^b   Kikuno, Nobuyuki ^b   Adachi, Hiroyuki ^b   Yoneda, Tatsuaki ^b   Kishi, Hirofumi ^b   Shigeno, Kazushi ^b   Konety, Badrinath R ^a   Igawa, Mikio ^b   Dahiya, Rajvir ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SHIMANE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BETA CATENIN; BISULFITE; CYCLIN D1; INHIBITOR PROTEIN; MESSENGER RNA; MYC PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; WNT INHIBITORY FACTOR 1; WNT PROTEIN;

ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; BLADDER MUCOSA; CELL GROWTH; CHROMOSOME 12Q; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION; GENE LOCUS; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BASE SEQUENCE; BETA CATENIN; CARCINOMA, TRANSITIONAL CELL; CARRIER PROTEINS; CELL LINE, TUMOR; CYCLIN D1; DNA MODIFICATION METHYLASES; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PROTO-ONCOGENE PROTEINS C-MYC; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS; WNT PROTEINS;

EID: 31544468969     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1344     Document Type: Article

References (36)

1. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000;103:311-20.
2. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-12.
3. Tetsu O, McCormick F. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-6.
4. Stein JP, Grossfeld GD, Ginsberg DA, et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 1998;160:645-59.
5. Polakis P. Wnt signaling and cancer. Genes Dev 2000;14:1837-51.
6. Morin PJ. β-Catenin signaling and cancer. Bioessays 1999;21:1021-30.
7. Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis-a look outside the nucleus. Science 2000;287:1606-9.
8. Fodde R. The APC gene in colorectal cancer. Eur J Cancer 2002;38:867-71.
9. Lako M, Strachan T, Bullen P, et al. Isolation, characterisation and embryonic expression of WNT11, a gene which maps to 11q13.5 and has possible roles in the development of skeleton, kidney and lung. Gene 1998;219:101-10.
10. Bui TD, O'Brien T, Crew J, et al. High expression of Wnt7b in human superficial bladder cancer vs invasive bladder cancer. Br J Cancer 1998;77:319-24.
11. Shiina H, Igawa M, Shigeno K, et al. β-Catenin mutations correlate with over expression of C-myc and cyclin D1 genes in bladder cancer. J Urol 2002;168:2220-6.
12. Stoehr R, Krieg RC, Knuechel R, et al. No evidence for involvement of β-catenin and APC in urothelial carcinomas. Int J Oncol 2002;20:905-11.
13. Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003;116:2627-34.
14. Stoehr R, Wissmann C, Suzuki H, et al. Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest 2004;84:465-78.
15. Hsieh SY, Hsieh PS, Chiu CT, et al. Dickkopf-3/REIC functions as a suppressor gene of tumor growth. Oncogene 2004;23:9183-9.
16. Suzuki H, Watkins DN, Jair KW, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004;36:417-22.
17. Kobayashi K, Ouchida M, Tsuji T, et al. Reduced expression of the REIC/Dkk-3 gene by promoter-hypermethylation in human tumor cells. Gene 2002;282:151-8.
18. Hsieh JC, Kodjabachian L, Rebbert ML, et al. A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 1999;398:431-6.
19. Wissmann C, Wild PJ, Kaiser S, et al. WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 2003;201:204-12.
20. Mazieres J, He B, You L, et al. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 2004;64:4717-20.
21. Sobin LH, Wittekind Ch, editors. TNM classification of malignant tumours. 6th ed. Geneva: International Union Against Cancer: 2002.
22. Dahiya R, Lee C, McCarville J, et al. High frequency of genetic instability of microsatellites in human prostatic adenocarcinoma. Int J Cancer 1997;72:762-7.
23. Enokida H, Shiina H, Igawa M, et al. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res 2004;64:5956-62.
24. Ogishima T, Shiina H, Breault JE, et al. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin Cancer Res 2005;11:1028-36.
25. Shiina H, Breault JE, Basset WW, et al. Functional loss of the γ-catenin gene through epigenetic and genetic pathways in human prostate cancer. Cancer Res 2005;65:2130.
26. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002;18:1427-31.
27. Reguart N, He B, Xu Z, et al. Cloning and characterization of the promoter of human Wnt inhibitory factor-1. Biochem Biophys Res Commun 2004;323:229-34.
28. Wong SC, Lo ES, Lee KC, et al. Prognostic and diagnostic significance of β-catenin nuclear immunostaining in colorectal cancer. Clin Cancer Res 2004;10:1401-8.
29. Karim R, Tse G, Putti T, et al. The significance of the Wnt pathway in the pathology of human cancers. Pathology 2004;36:120-8.
30. Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 1997;11:3286-305.
31. Taniguchi H, Yamamoto H, Hirata T, et al. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene 2005;24:7946-52.
32. Hrzenjak A, Tippl M, Kremser ML, et al. Inverse correlation of secreted frizzled-related protein 4 and β-catenin expression in endometrial stromal sarcomas. J Pathol 2004;204:19-27.
33. He B, Lee AY, Dadfarmay S, et al. Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in β-catenin-deficient human mesothelioma cells. Cancer Res 2005;65:743-8.
34. Hsieh SY, Hsieh PS, Chiu CT, et al. Dickkopf-3/REIC functions as a suppressor gene of tumor growth. Oncogene 2004;23:9183-9.
35. Bryan RT, Nicholls JH, Harrison RF, et al. The role of β-catenin signaling in the malignant potential of cystitis glandularis. J Urol 2003;170:1892-6.
36. Caldwell GM, Jones C, Gensberg K, et al. The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res 2004;64:883-8.